Nanobiotix’s Post

How do CEOs of CDMOs navigate uncertainty and drive growth? Find out during the 2nd Annual Bioprocessing Venture, Innovation & Partnering Conference on August 21, 2024, in Boston, MA, part of CHI's Bioprocessing Summit. Hear from this all-star panel featuring industry leaders as they share their experiences, perspectives, and foresight on steering their organizations through dynamic and complex business landscapes to achieve sustainable growth and industry leadership. Ran Zheng (CEO, Landmark Bio) Steve Favaloro (President & CEO, Genezen) Patrick Lucy (President & CEO, RoslinCT) Rahul Singhvi (Co-Founder & CEO, Resilience) Gain insights into strategies for navigating market volatility, balancing short-term pressures with long-term goals, overcoming regulatory challenges, leveraging technology for innovation, and fostering resilience within organizations. Don’t miss this opportunity to connect with key players driving the future of bioprocessing. For more details, visit https://lnkd.in/gzryU8G2 #bioprocessing #innovation #biotech #conference #partnerships #CDMO #CEO

In an industry like #biotech where the stakes are as high as the potential impact, harsh financial environments like we are in now can be challenging to navigate. In this piece, CEO Lisa Ricciardi shares five attributes of biotech organizations that allow them to thrive and grow, even in a landscape such as this: 👉 High-quality science 👉 Proven target engagement 👉 Rigorous Phase 2 #ClinicalTrials 👉 Enrolling patients, not "subjects" 👉 Collaboration with the scientific community By leaning into these five qualities, biotech companies can create solid strategies for #growth and success. #LifeSciences #Leadership

💼 Bold View Capital is making bold investments in tomorrow’s biotech leaders. Visit Booth #800 at SynBioBeta 2025 and discover how they’re fueling the future of biotech innovation. Register today to connect with their team! #SynBioBeta #BiotechFundingFutures #BoldInvestmentsInScience #FutureOfBiotech

Our CEO, Erik van den Berg shares his perspective on navigating biotech's evolving landscape in his latest thought leadership piece in Life Science Leader. From capital efficiency to clinical innovation, he discusses key lessons learned from leading through unprecedented industry changes and why there's optimism ahead for 2025. Read his insights here: https://lnkd.in/ewakbq_u #Leadership #Biotech #MTx #MemoTherapeuticsAG 

At this year’s Galien Forum, we focused on transformative shifts in the biopharma industry, especially in the wake of COVID-19. Our discussions highlighted how intelligent technologies and AI are driving advances in drug discovery, reducing investment risks, and enabling personalized healthcare - paving the way for faster access to medicines and better economic outcomes for companies and healthcare systems alike. We also explored new collaboration models with biotech and academia, while expanding our scope beyond oncology to address metabolic diseases and neuro-related conditions. Insights on aging populations and constrained healthcare budgets underscored the need to keep science at the heart of our efforts as we embrace innovation. Looking ahead, these advancements inspire optimism for a healthcare ecosystem that is more efficient, accessible, and truly transformative for patient care. My heartfelt thanks to my co-host, Dr. Michael Rosenblatt, and our distinguished panelists, Dr. Noubar Afeyan, John F. Crowley, and Christopher Viehbacher, Biogen, for sharing their invaluable perspectives during the 2024 CEO Panel Discussion. Thank you all for your commitment to advancing science and healthcare. I look forward to our continued collaboration in this dynamic field! #GalienForum2024 #Biotechnology #HealthEquity

Our CEO Simon Chandler will be attending Sidley’s highly anticipated event on Deal and Investment Activity in Life Sciences and Healthcare Innovation at the Crick on the 24th September. 🔗 https://lnkd.in/eKKvvDpe This conference brings together top minds from pharma, biotech, healthcare, private equity, and venture capital to discuss critical trends, issues, and opportunities that are shaping the future of healthcare and life sciences. With a stellar lineup of industry leaders from companies like AstraZeneca, Novartis, J.P. Morgan, Flagship Pioneering, and more, we are looking forward to insightful panels on key topics such as: 💡 Private Equity Outlook – What's next for PE investment in healthcare and life sciences? 🤖 Artificial Intelligence – Exploring AI's growing role as a transformative investment opportunity. 💼 Pharma Business Development – The future of M&A, licensing, and collaborations across biotech. 💰 Venture/Growth Capital – How global funds are navigating today’s market and where they see the brightest opportunities. We would also welcome conversations with potential investors and partners who are interested to learn more about Rinri Therapeutics mission to develop regenerative therapies for sensorineural hearing loss. Whether you’re attending in person or virtually, we look forward to connecting with fellow industry professionals and exchanging ideas on the future of innovation in healthcare. Stay tuned for updates and takeaways! #LifeSciences #HealthcareInnovation #Investment #PrivateEquity #VentureCapital #AI #Pharma #HealthcareDeals #SidleyHIC2024

Lots of discussion about AI - what about AI supported CRO activity, a new age of how we manage and track clinical study progress and outcomes

Just as the great achievements of Middle Eastern vision and modern technology have shaped the world’s tallest structures, I believe similar collaborations can transform global healthcare. At MirZyme Therapeutics, inspired by the values of compassion and service central to my faith, we are working to make preeclampsia history. By blending innovative science with a shared purpose, we can achieve breakthroughs that save lives and leave a lasting legacy. These architectural marvels are a testament to what is possible when leadership, vision, and technology converge. Yet they also raise a critical question: while progress increasingly emerges from regions beyond the traditional centres of innovation, why does scientific advancement remain so concentrated in certain parts of the world? As we enter a new year filled with hope and promise, how can we ensure that the transformative power of innovation becomes truly global, accessible to all, and inclusive of every region’s potential?

🌟 Top 10 Reasons to Attend NEBCO 2025 🌟 🚀 1. Industry Expertise Under One Roof  Join top leaders and decision-makers across healthcare, life sciences, pharmaceuticals, medical devices, and more, all driving innovation forward. 💡 2. Cutting-Edge Insights  Explore the latest trends in life sciences, digital marketing, and data analytics, and discover what’s shaping the future of these industries. 🤝 3. High-Impact Networking  Meet and connect with key players and thought leaders who are redefining the New England biosciences landscape. 💼 4. Business Development & Lead Generation  Unlock new business opportunities and foster strategic partnerships with leaders who are laser-focused on driving growth in life sciences. 💬 5. Collaboration at its Core  NEBCO 2025 is all about fostering meaningful collaborations that lead to real-world solutions. Expand your network and knowledge base! 🔍 6. Investment Opportunities  Engage directly with investment banks specializing in the life science industry and discover new avenues for growth, funding and M&A. 🌱 7. Focus on Innovation  Immerse yourself in the latest R&D breakthroughs and emerging technologies that are changing healthcare, biotech, and pharma. 🎯 8. Strategic Vision & Leadership  Learn from top-to-top leaders as they share their strategic vision for the future of life sciences and healthcare across New England and beyond. 📊 9. Data-Driven Decision Making  Understand how data analytics is revolutionizing life sciences and healthcare, and gain practical insights into leveraging data for better outcomes. 💼 10. Stay Ahead of the Curve  Position yourself at the forefront of innovation and trends by attending this must-visit conference for anyone serious about advancing in life sciences. 🚀 Don't miss out on the chance to be part of NEBCO 2025—where the future of life sciences takes shape! #NEBCO2025 #LifeSciences #HealthcareInnovation #TopToTopConference #BusinessDevelopment #NewEnglandBiotech #InvestmentOpportunities #BioCT #YaleVentures

“Innovation is at the core of our business.” — Arjen Lemmen, VP of Corporate Development & Strategy at argenx. I'm happy to share my latest article for BiotechNews & Life Sciences that dives deep into Argenx, an example of biotech innovation emanating from Belgium! In my conversation with Arjen, we explored: • The remarkable transformation of Argenx from a platform company to a global leader with over 1,500 dedicated 'Argonauts' • The successful launch of VYVGART, a groundbreaking treatment for generalized myasthenia gravis • The integral role of innovation in shaping Argenx's culture and operational strategies • The significance of partnerships within the Belgian biotech ecosystem • How resilience and adaptability have allowed Argenx to navigate challenges in clinical trials and financing Argenx’s journey exemplifies how combining scientific rigor with entrepreneurial spirit can lead to groundbreaking advancements in healthcare.